Cambridge Healthtech Institute’s Inaugural

Drug Discovery for Rare Diseases

Focus on Genomic and Proteomic Targets and Drug Modalities

March 28, 2018 | Boston Marriott Cambridge | Cambridge, MA

Rare diseases, or diseases that affect only a small percentage of the population, have been growing in significance and prominence in recent years. According to the National Institutes of Health, there are nearly 7000 rare diseases and more than 25 million Americans who are affected. Approximately 80% of these rare diseases are genetic in origin. Cambridge Healthtech Institute’s symposium on Drug Discovery for Rare Diseases will bring together leading scientists, clinicians, executives and experts who are deeply involved in bringing to market the treatments for such rare disorders. This symposium will bring to light some of the new drug targets, and peptide and oligonucleotide-based drug modalities that are being pursued. This unique one-day event will bring together people from diverse backgrounds to tackle translational challenges and to discuss potential opportunities in this field. The goal is to help attendees and sponsors meet scientific and technical experts who are involved in rare disease research to exchange ideas and set up collaborations.

Who should attend: Scientists, Lab Managers, Clinicians, Team Leads, Directors and Executives from Pharma, Biotech, Academia, Government, Contract Research Labs and Technology Providers involved in Drug Discovery & Development, Functional Screening, Target Identification and Validation, Biomarker Discovery, Translational and Clinical Research, Bioinformatics, Diagnostics, Alliance Management, and other areas important to Rare Diseases.

Topics will include, but are not limited to:

  • Update on peptide and oligonucleotide drugs for treating rare diseases
  • Evaluating new models and approaches to identify novel drug targets and biologic modalities
  • Using CRISPR, stem cells, and other innovative tools for understanding and treating rare diseases
  • Finding computational and bioinformatics tools for identifying disease pathways and drug targets
  • Exploiting proteomics, genomics, and metabolomics tools for drug and target discovery
  • Exploring gene therapy, cell therapy, and gene editing

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for submission is September 15, 2017.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:
Tanuja Koppal, Ph.D.
Conference Director
Cambridge Healthtech Institute
E: tkoppal@healthtech.com

For partnering and sponsorship information, please contact:
Carolyn Benton
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5412
E: cbenton@healthtech.com